ACQUISITIONS and MERGERS

The acquisition will strengthen both Radiant Logic and Brainwave GRC’s respective market positions as identity, analytics and intelligence experts by offering a new lightweight data-centric governance capability and a market-defining identity data intelligence platform.

"Today’s announcement is good news for our stakeholders and the Reducer program," said Fred Colen, President and CEO of Neovasc. "We have made tremendous strides building accelerating revenue, clinical data, commercial reimbursement, and a fantastic team, and now it’s time to take the next step to accelerate Reducer adoption globally. The team at Shockwave has demonstrated an extraordinary ability to scale novel technologies and build value for patients, customers and investors, and we are thrilled to become a part of their organization."

Ekso Bionics President and COO Scott Davis promoted to Chief Executive Officer; and Steven Sherman to remain Chairman, appointed Executive Chair.

"Endoluminal surgery is an emerging field and a core focus for our Endoscopy business," said Mike Jones, senior vice president and president, Endoscopy, Boston Scientific. "We intend to expand our global capabilities in ELS with the differentiated innovation that Apollo Endosurgery offers, and we will continue to focus on procedural adoption as well as professional education in this exciting space. This acquisition also enables us to enter a new adjacency – the endobariatric market – and deliver strong, continued growth across our business."

Dvir Cohen, CEO and Co-Founder of Momentis. “In the months ahead, we will continue our efforts to broaden availability of the system and improve gynecological surgery to enable more surgeons to perform the clinically preferred transvaginal approach, setting a higher standard in women’s healthcare.”

The Anovo Surgical System is the first and only FDA-authorized surgical robot with features including shoulder, elbow, and wrist joints designed to mimic human arms and provide human level dexterity.

By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Limus Release) drug-eluting balloon.

Sebia advises Zeus Scientific, will provide synergies and expand their capabilities and product portfolio in autoimmunity, with a strong footprint in the United States.

"This acquisition is a great fit for CHS because we share similar qualities, values, capabilities and offerings. The MISI acquisition is a great platform for US expansion in the diagnostic imaging market," states Mike Canzoneri, President and CEO of CHS USA.